Author's posts
A Spark Of Good News For Precision Oncology In Breast Cancer
In a trial of metastatic triple-negative breast cancer, AZD5363 significantly extended patients’ overall survival from 12.6 to 19.1 months, vs. placebo, when given with chemotherapy.
Not So Fast With Immune Therapy For Breast Cancer
Does this medicine offer the best shot at improving survival or quality-of-life, among all drugs approved or available in clinical trials?
